预测未治疗淋巴管肌瘤病患者的个体化肺病进展
该研究基于美国NHLBI淋巴管肌瘤病登记处(216例)和英国淋巴管肌瘤病自然病史队列(185例),利用诊断时年龄、绝经状态、基线FEV1和DLCO等常规变量,构建联合模型动态预测未接受西罗莫司治疗的LAM患者临床相关FEV1下降概率及5年无移植生存率。推导队列和验证队列AUC均>0.80(约0.80),模型可提供预测FEV1、FEV1下降速率及FEV1持续下降风险概率。工具已在线免费开放,作者认为纵向建模有助于个体化预后评估和治疗启动时机决策。
要点
- 模型适用于未接受西罗莫司治疗的LAM患者,可个体化预测FEV1下降风险和5年无移植生存概率。
- 推导队列(NHLBI登记处,216例)和外部验证队列(英国自然病史队列,185例)AUC均>0.80(约0.80)。
- 预测因子包括诊断时年龄、绝经状态、基线FEV1和DLCO,均为常规可获取变量。
- 模型可输出预测FEV1、FEV1下降速率及FEV1持续下降风险概率,辅助治疗启动时机决策。
- 在线工具已免费开放(https://anushkapalipana.shinyapps.io/testapp_v2/)。
适用人群与场景
- 美国NHLBI淋巴管肌瘤病登记处和英国淋巴管肌瘤病自然病史队列中观察的LAM患者。
- 未接受西罗莫司治疗的患者(模型用于未治疗患者)。
研究设计与关键结果
- 研究类型:动态预测模型开发与外部验证,使用美国NHLBI淋巴管肌瘤病登记处(216例)和英国淋巴管肌瘤病自然病史队列(185例)。
- 模型基于诊断时年龄、绝经状态、基线FEV1和DLCO等常规变量,采用随机建模,预测临床相关FEV1下降概率。
- 联合模型准确估计未接受西罗莫司治疗的LAM患者未来肺功能下降风险和5年无移植生存概率,AUC约0.80。
- 模型提供预测FEV1、FEV1下降速率及FEV1持续下降风险概率,推导队列和验证队列AUC均>0.80。
证据类型、等级与局限
- 证据类型:预测模型开发与外部验证研究(队列数据)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对未接受西罗莫司治疗的LAM患者,该模型可个体化估计FEV1下降风险和5年无移植生存概率,辅助决定治疗启动时机。
- 模型使用常规变量(年龄、绝经状态、基线FEV1和DLCO),便于临床获取。
- 在线工具可免费使用(https://anushkapalipana.shinyapps.io/testapp_v2/)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Lung function decline varies significantly in patients with lymphangioleiomyomatosis (LAM), impeding individualized clinical decision-making.
RESEARCH QUESTION: Can we aid individualized decision-making in LAM by developing a dynamic prediction model that can estimate the probability of clinically relevant FEV1 decline in patients with LAM before treatment initiation?
STUDY DESIGN AND METHODS: Patients observed in the US National Heart, Lung, and Blood Institute (NHLBI) Lymphangioleiomyomatosis Registry were included. Using routinely available variables such as age at diagnosis, menopausal status, and baseline lung function (FEV1 and diffusing capacity of the lungs for carbon monoxide [Dlco]), we used novel stochastic modeling and evaluated predictive probabilities for clinically relevant drops in FEV1. We formed predictive probabilities of transplant-free survival by jointly modeling longitudinal FEV1 and lung transplantation or death events. External validation used the UK Lymphangioleiomyomatosis Natural History cohort.
RESULTS: Analysis of the NHLBI Lymphangioleiomyomatosis Registry and UK Lymphangioleiomyomatosis Natural History cohorts consisted of 216 and 185 individuals, respectively. We derived a joint model that accurately estimated the risk of future lung function decline and 5-year probabilities of transplant-free survival in patients with LAM not taking sirolimus (area under the receiver operating characteristic curve [AUC], approximately 0.80). The prediction model provided estimates of forecasted FEV1, rate of FEV1 decline, and probabilities for risk of prolonged drops in FEV1 for untreated patients with LAM with a high degree of accuracy (AUC > 0.80) for the derivation cohort as well as the validation cohort. Our tool is freely accessible at: https://anushkapalipana.shinyapps.io/testapp_v2/.
INTERPRETATION: Longitudinal modeling of routine clinical data can allow individualized LAM prognostication and assist in decision-making regarding the timing of treatment initiation.
参考来源
- Palipana AK, Gecili E, Song S, et al. Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis. Chest. 2023. PMID: 36610667. doi:10.1016/j.chest.2022.12.027
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。